Pluri Inc (PLUR) News

Is plant cell culture a scalable way to futureproof cocoa and coffee?

https://agfundernews.com/is-plant-cell-culture-a-scalable-way-to-futureproof-cocoa-and-coffee

IMO...Today's Announcement Makes It Much More Likely, That A United States DoD 12,000 Dose 100 Million Dollar Plus Stock-Piling Deal Is Coming ? Fingers Crossed !!!

https://www.globenewswire.com/news-release/2018/04/30/1489762/0/en/U-S-FDA-Clears-Pluristem-s-IND-to-Treat-Victims-Exposed-to-Acute-Radiation.html

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine’s Radiation Emergency Preparedness

https://pluri-biotech.com/releases/pluri-announces-exclusive-collaboration-agreement-with-hemafund-to-enhance-ukraines-radiation-emergency-preparedness/

March Company Presentation !!!

https://pluri-biotech.com/presentation/

Coffeesai

Bu¨hler makes new collaboration for cultivated meat

https://www.feedandadditive.com/buhler-makes-new-collaboration-for-cultivated-meat/

Today.....AACR IO 2025 | AACR | Meetings

Chief Scientific Officer Dr. Arthur Machlenkin will be giving a poster session titled “Advancing the allogeneic MAIT platform for targeting solid tumors” on Monday, February 24, 1:45-4pm

Strategic Collaboration for Scalable Cultivated Meat Production

Foodtech innovator Ever After Foods (EAF) and global food leader Bühler have announced a strategic collaboration to accelerate the commercial-scale production of cultivated meat. This partnership aims to provide food producers worldwide with efficient, cost-effective, and scalable cultivated meat production systems, addressing global food security and environmental challenges.

“The global food chain faces significant challenges if we are to successfully and sustainably feed our growing population. Powering cultivated meat production at scale with a patented production system, EAF will help the food industry keep pace with protein demands,” — Ian Roberts, CTO, Bühler

https://igrownews.com/ever-after-foods-latest-news/

Ever After Foods is now working closely with selected cultivated meat companies and food industry leaders to accelerate the development and deployment of its proprietary edible packed-bed (EPB™) technology platform.

https://vegconomist.com/manufacturing-technology/ever-after-foods-buhler-commercial-cultivated-meat-production-system/

Israel’s Ever After Foods has partnered with Swiss manufacturing giant Bühler Group to produce cultivated meat at a mass scale with much smaller equipment.

https://www.greenqueen.com.hk/buhler-ever-after-foods-tnuva-cultivated-meat-bioreactors/

Why doesn’t anyone ask why the company’s been around for a quarter century now and has yet to make any revenues. Where did the half billion dollars they’ve raised during that time go?

Q&A with Yaky Yanay, President and CEO, Pluri

https://www.citybiz.co/article/660081/qa-with-yaky-yanay-president-and-ceo-pluri/

February Company Presentation !!!

https://pluri-biotech.com/presentation/

Like the 20 other markers they’ve entered, they’ll get the usual 0# market share. Unless they enter the clown nose market. Then they’d have a monopoly.

So George is good then?

Israel’s Pluri secures $6.5M strategic Investment, Enters Cacao market

According to reports. Global cacao market value was $13.5 billion in 2023, and is expected to grow by 8.2% to $23.5 billion by 2030

https://agrospectrumasia.com/2025/01/27/israels-pluri-secures-6-5m-strategic-investment-enters-cacao-market.html

Ok there bud. How’s George doing? You know, your boss.

Thanks For Confirming That You Are Completely Clueless !!!

What’s clueless eh? That they’re around 0 in shareholder equity? How much cash they got left? What’s it take to pay the 150 plus employees each quarter. That $10 million buys them what, 4 or 5 months? What’s gonna happen once they hit the pinks since they won’t regain compliance based on shareholder equity. Ya this is the year the cash cow for employees ends. The scams coming to an end soon.

Scotty.....We Enjoy Your Profound Cluelessness !!! Keep The Comedy Coming !!!

That should get them to about 0 in shareholder equity. No compliance comprende. Belly up this year.

Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million

https://pluri-biotech.com/releases/pluri-secures-additional-3-5-million-investment-from-major-shareholder-at-premium-to-market-bringing-total-recent-financings-to-10-million/

“The first cost estimates that we have applying Pluri’s technology into the production of Kokomodo cacao are very promising and will give Kokomodo a tremendous competitive advantage in this vertical.”

Asked about scaling plant cell culture, he added: “From day one, we have been growing cells in packed bed reactors that allow us to achieve real scale in relatively small bioreactors as our system is 20 times more efficient than a [typical] steel bioreactor [where cells grow in suspension].

“Our plan is to move aggressively and quickly to bring these solutions to market and our first step is to use bioreactors with five chambers of 200 liters capable of producing hundreds of kilos of cocoa and coffee. We anticipate that in 2026 this system will be available from Pluri for manufacturing across our subsidiaries. So when I’m talking about scaling up, it’s not a 10-year process, this is something that we see coming and coming soon.”

He added: “We are already discussing with players in the [coffee and chocolate] industry that are showing very significant interest in our solutions.”

Weinstein explained: “This is one of those rare opportunities you find in life as an investor, when you look at the quality of the people and the technology, it’s quite unique. The potential is explosive.

https://agfundernews.com/is-plant-cell-culture-a-scalable-way-to-futureproof-cocoa-and-coffee

New Company Presentation !!!

https://pluri-biotech.com/presentation/

Wow cocoa now. First the pretend steaks, then pretend coffee and now pretend cacao. Pretty good for a pretend company that’s going to the pinks in a few months.

Kokomodo: This Israel-based company uses cell-cultured technology to navigate supply chain challenges by creating real, controlled, climate-resilient cocoa. This allows cocoa to be consistently produced year-round and anywhere in the world without relying on specific climates.

Pluri is acquiring a 71% stake in Kokomodo Ltd.

https://ir.mondelezinternational.com/news-releases/news-release-details/mondelez-international-selects-10-start-ups-participate-second

Yaky Yanay, Chief Executive Officer and President of Pluri. “We are pleased that Mr. Weinstein understands our mission and will take part in shaping our strategy as we progress. We believe that Mr. Weinstein’s equity investment will strengthen our financial foundation and allow us to advance our entry into the cultivated cacao market, with the goal of positioning Pluri as a leader in this sector, where demand is growing and alternative agricultural solutions are needed to feed our global population. We believe that the synergy between Kokomodo’s advancements in cell line development and Pluri’s industrial-scale production creates a strong foundation for innovation, positioning the company to lead the field of cultivated cacao and set new benchmarks in cultivated cacao technologies.”

IMO....Pluri Will Control The Cultured Chocolate Market ! $$$/b]

Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of Directors
Pluri to purchase approximately 71% of Kokomodo Ltd.’s shares, a leading AgTech company focused on the production of cacao, subject to shareholder approval.

https://pluri-biotech.com/releases/pluri-secures-6-5-million-strategic-investment-at-premium-to-market-enters-cacao-market-through-acquisition/

Pluri CEO & President Yaky Yanay

Pluri CEO & President Yaky Yanay

Nasdaq has determined to grant the Company an extension of time to regain compliance with the Stockholders’ Equity Requirement until May 24, 2025.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported, on November 25, 2024, Pluri Inc., or Pluri or the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital Market, or the Stockholders’ Equity Requirement, nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.

On January 6, 2025, the Company submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq has determined to grant the Company an extension of time to regain compliance with the Stockholders’ Equity Requirement until May 24, 2025. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal Staff’s determination to a Hearings Panel.

The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance the Company will ultimately regain compliance with all applicable requirements for continued listing.

Neither the Nasdaq Letter nor the Company’s noncompliance have an immediate effect on the listing or trading of the Company’s common shares, which will continue to trade on The Nasdaq Capital Market under the symbol “PLUR”.

A non event, eh FDA?

MORE MAIT CELL INDICATIONS !!!

In some embodiments, there is provided a method for treating a subject suffering from an autoimmune disease or disorder, comprising administering to said subject a composition comprising the population of engineered IVB CAR-MAIT cells disclosed herein. In some embodiments, the engineered IVB CAR-MAIT cells are allogeneic to said subject. In some embodiments, the autoimmune disease or disorder comprises systemic lupus erythematosus (SLE), refractory SLE, pemphigus vulgaris, multiple sclerosis, type I diabetes, rheumatoid arthritis, celiac disease, pernicious anemia, inflammatory myopathies, myasthenia gravis, or adrenalitis, or a combination thereof.
In other embodiments, there is provided a method of treating a subject infected with a pathogen, comprising administering to the subject a composition comprising a population of placental IVB CAR-MAIT cells, wherein the IVB MAIT cells are allogeneic to said subject.

In certain embodiments, these IVB MAIT cells do not comprise an exogenous antigen receptor. In some embodiments, the pathogen is a bacterial pathogen, a viral pathogen, or a fungal pathogen. In certain embodiments, a bacterial pathogen comprises an antibiotic resistant bacteria or bacterial treatment resistant bacteria. In some embodiments, a bacterial pathogen comprises a

Mycobacterium tuberculosis bacteria. In some embodiments, a fungal pathogen comprises an invasive Aspergillus. In some embodiments, a viral pathogen comprises a cytomegalovirus, a hepatitis B virus, or a hepatitis C virus. In some embodiments, the infectious condition treated by a method disclosed herein, is limited to site specific infections, for example wherein an infection is limited to a specific site or organ. In some embodiments, an infection treated by a method disclosed herein comprises a post-surgical infection.

MAIT CELL PATENT !!!

In some aspects of the invention, the cell composition disclosed herein is for use in therapy. In some optional embodiments, the cell composition may be used for treating a subject having a tumor or malignancy. Exemplifying use of the cell composition of the invention is for a subject afflicted with a tumor such as, but not limited to: blood cancer, melanoma, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovary cancer, pancreatic cancer, prostate cancer, uterine cancer, cervical cancer, bladder cancer, stomach cancer, head and neck cancer, brain cancer, skin cancer and sarcoma.

In some aspects of the invention a method of treating a subject having a tumor or malignancy is provided, wherein the method comprises administering to the subject a cell composition according to any optional embodiment as defined above. The tumor treated may be for example, blood cancer, melanoma, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovary cancer, pancreatic cancer, prostate cancer, uterine cancer, cervical cancer, bladder cancer, stomach cancer, head and neck cancer, brain cancer, skin cancer and sarcoma. Preferably, but not necessarily, the cell composition for treating the subject is adapted for cell therapy and the population comprises at least 109 viable cells, of which at least 90% are TCRVa7.2+ CD161hlgh.

In some embodiments, the engineered placental MAIT cells used for treating the subject are allogeneic to said subject. In other options, the engineered placental MAIT cells are partly histocompatible with the subject, or the engineered placental MAIT cells are not histocompatible with the subject.

In some aspects of the invention, a method of treating a subject infected with a pathogen is provided. The pathogen may be either one of a bacterial pathogen, viral pathogen, or a fungal pathogen, and the method comprises administering to the subject a cell composition according to any suitable optional embodiment as defined above.

In some additional aspects of the invention, method of treating a subject suffering from a fibrotic disease or condition, method of treating a subject suffering from a senescence-associated disease or condition, method of treating a subject having an allogeneic transplantation, method of treating a subject suffering from an autoimmune disease or disorder, are provided, wherein all methods above comprising administering to the subject in need a cell composition according to any suitable optional embodiment as defined above.

Yet, in accordance with additional aspects of the invention, a method of treating a subject infected with a pathogen is provided, the method comprising administering to the subject a composition comprising a population of MAIT cells derived from placenta. The population of MAIT cells according to this embodiment is not engineered MAIT cells, and the cells do not express exogenous CAR. The pathogen may be for example, a bacterial pathogen, a viral pathogen, or a fungal pathogen. In some specific examples the bacterial pathogen may comprise a Mycobacterium tuberculosis bacteria. In some embodiments, the bacterial pathogen comprises an antibiotic resistant bacteria or bacterial treatment resistant bacteria. In some other specific examples, the fungal pathogen may comprise an invasive Aspergillus. In some further examples, the viral pathogen may comprise a cytomegalovirus, a hepatitis B virus, or a hepatitis C optionally the infection is as a result of a post-surgical infection. Preferably, but not necessarily, the MAIT cells used for treating the subject according to this aspect of the invention are allogeneic to said subject.

2 Very Important Pluri MAIT Cell Patents Posted Today !!!

https://patentscope.wipo.int/search/en/result.jsf?_vid=P11-M5ZHNP-55415

Yaky Yanay: Revolutionizing Biotech with Pluri's Cell-Based Solutions

Cellular Agriculture Redefines The Future Of Coffee

https://stir-tea-coffee.com/tea-coffee-news/cellular-agriculture-redefines-the-future-of-coffee/

They pretend cured Covid, IC, ICS, Beurgers, Solid Tumours, Preeclampsia, ARS, Hip and others I’m sure over forgotten over the decades. So why not pretend cure cancer too.

Pretend all the way to the pinks with -$10,000,000.00 in shareholder equity.

Can a Placenta Cure Cancer?

BIU’s collaboration with biotechnology company Pluri suggests it can

https://www.biu.ac.il/en/article/582414#:~:text=At%20the%20heart%20of%20this%20research%20lies%20a,MAIT%20cells%20from%20placentas%20donated%20by%20healthy%20women.

Should only see about another 4 or 5 of these before they finally shut this company runs out of money. Took 25 years but 2025 will mark the end of this legal scam. Those 150 employees plus will milk every last penny they can, and most likely steal whatever they can from the office. They were taught well by the head clowns.

-$10,000,000.00 in shareholder equity.
Trading at fresh ALL TIME lows
Nuf said

January Company Presentation !!!

https://pluri-biotech.com/presentation/

New all time lows to go along with the nearly -10,000,000.00 in shareholder equity. Keep an eye out on the Israeli Kijiji. They’re going to be selling office furniture real soon.

How they gonna overcome almost -$10,000,000.00 in shareholder equity. The one that’s gonna get them on the pinks. But the $500,000,000.00 that they’ve blown with nothing to show for it becomes irrelevant when you look at the big picture. Like the good ole Zzatt used to say, “WE GOT ZZIENTISTS” wonder how his 200,000 shares are doing.

“For us, it’s not just a theoretical exercise, we can produce hundreds of kilos in our labs. This is not something that we intend to develop in five years’ time; we know how to scale this process.” Yaky Yanay, CEO, Pluri

https://agfundernews.com/eggs-coffee-chocolate-and-the-culture-wars-foodtech-in-2024

PLUR under $5

Not when you’re around - $9 million in shareholder equity. That’s what happens when you blow through half a billion dollars with literally zero to show for it. Even the pr says ARS will s all they got on the go and we all know they failed on that one already.

Clowns are just about done with their schemes to dupe investors out of their money.

This Bodes Well For The Space !!!

The FDA granted approval of Ryoncil to Mesoblast, Inc.

https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host

-$5,283,000 shareholder equity as of Sept 30th. They lost over $6,000,000 last quarter so by now with a bit more than half a month to go in this quarter, they should be hitting -$10,000,000 in shareholder equity.

Next stop…the pinks.

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

https://pluri-biotech.com/releases/u-s-national-institutes-of-health-to-fund-4-2-million-contract-to-advance-development-of-pluris-plx-r18-in-conjunction-with-u-s-dod-as-a-medical-countermeasure-for-hematopoietic-acute-radi/

4.8315 -0.1685 (-3.37%)
As of 9:45:46 AM EST. Market Open.
Volume 30,082
Avg. Volume 25,828
Wow, the market sure is impressed!